When to use model-informed drug development (Ep. 52)
This episode is a collection of my thoughts on model-informed drug development and where different modeling modalities fit into the development schedule. These are just my opinions and each development program is different.Links discussed in the show:You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Clinical Pharmacology Podcast with Nathan Teuscher
Beyond Small Molecules—Allometric Scaling for Biologics and Engineered mAbs (Ep. 58)
Bioequivalence Testing: The Stats Behind Generic Drug Approvals (Ep. 57)
Examining Volume of Distribution (Ep. 56)
Talking about data science with Mike Stackhouse (Ep. 55)
Get summaries like this every morning.
Free AI-powered recaps of Clinical Pharmacology Podcast with Nathan Teuscher and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.